Mafena Tablet is a combination pharmaceutical formulation containing Drotaverine 80mg and Mefenamic Acid 250mg, designed for the effective management of pain associated with smooth muscle spasms. Drotaverine, an antispasmodic agent, acts by inhibiting phosphodiesterase-IV, leading to increased intracellular cyclic AMP levels and subsequent relaxation of smooth muscles, thereby alleviating spasmodic pain. Mefenamic Acid, a nonsteroidal anti-inflammatory drug (NSAID), exerts its analgesic and anti-inflammatory effects by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), resulting in decreased synthesis of prostaglandins responsible for pain and inflammation. The synergistic action of these two active ingredients makes Mafena Tablet particularly effective in treating conditions such as dysmenorrhea, abdominal cramps, renal colic, and other spasmodic pain disorders. It is indicated for short-term use under medical supervision to minimize potential adverse effects, including gastrointestinal discomfort, hypersensitivity reactions, and potential renal impairment. Caution is advised in patients with a history of peptic ulcer disease, cardiovascular conditions, or renal dysfunction. Mafena Tablet should be administered as per the prescribed dosage regimen, and patients are advised to report any unusual symptoms promptly. This combination therapy offers a comprehensive approach to managing spasmodic pain by targeting both muscle relaxation and inflammation.